drugset / Trial / NCT04778618

Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

NCT04778618 ↗

Phase 2 Unknown 63 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT).

Timeline

Start
2020-12-01
Primary completion
2022-07-31
Completion
2024-01-14

Outcome

Met primary endpoint

paper The outcomes in historical control were inferior to those of phase 2 trial cohort (CMV reactivation: 70.8%, p < .001; PMID 37706580 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 6 mg/kg Intravenous
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 10 mg/kg Intravenous